Xspray: Narrowing The Focus

Redeye adjusts estimates and fair value range for Xspray in light of the company’s change of focus to Dasynoc as its lead project, and its now exclusive targeting of improved generics. In our view, the longer-term prospects for Xspray are relatively intact, which we expect the market to realize as Dasynoc approaches launch, estimated in 2023

FE

Filip Einarsson

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.